Illumina Joins Singapore's SG-INSIGHT Study to Expand Genome Sequencing
Published
Illumina, a biotechnology company, has been selected to support SG-INSIGHT, a clinical study in Singapore. The study aims to expand whole-genome sequencing, which is a method that reads the complete genetic code of a person.
Whole-genome sequencing can help researchers understand how genes affect health and disease. By taking part in the project, Illumina will provide technology and support for the study. The company's role is intended to help reach more people and increase the number of genomes that can be analysed.
The report did not give full details about the size of the study, its timeline, or how much funding is involved. It also did not say how participants will be selected or when the first results might be available. These details are likely to be shared as the project develops.
The partnership shows Singapore's continued interest in genomic research and medical innovation. Readers who want to follow the project can look for further updates from the study's organisers and from Illumina.
Sources: Vietnam Investment Review - VIR
More Singapore news
- Singapore Needs More Tech Companies to Grow Its Stock Market, HSBC Strategist Says
- Singapore Tech Shares Rebound After Last Week's Sell-Off
- Databricks Plans to Double Its Singapore Team to 500 Staff
- Visa Sets Up Six Technology Hubs in New Singapore Centre
- US Congress Faces Possible Impeachment Fight Over Defence Secretary Pete Hegseth
- Giving Former Politicians Room to Return to Normal Life in Singapore
- Singapore Cloud Firm Megaspeed Faces Renewed US Scrutiny
- Iran Calls for Stronger Economic and Trade Ties with Singapore